Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 19/20 | 0.55 |
| ▸ | CCR3 | P51677 | 19/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3939200 | 1.00 | HRH1 (0.55) | HRH1CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3937095 | 1.00 | HRH1 (0.55) | HRH1CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1929370 | 0.83 | HRH1 (0.60) | HRH1CCR3KCNH2 | |
| SCHEMBL3941516 | 0.80 | CCR3 (0.45) | HRH1CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3949242 | 0.80 | CCR3 (0.45) | HRH1CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3941182 | 0.80 | KCNH2 (0.54) | HRH1CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4154387 | 0.79 | HRH1 (0.61) | HRH1CCR3KCNH2 | |
| SCHEMBL3939435 | 0.78 | HRH1 (0.46) | HRH1CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3942734 | 0.78 | HRH1 (0.46) | HRH1CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5338616 | 0.77 | HRH1 (0.69) | HRH1CCR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238691-B2 | Piperidine derivatives and their use as modulators of chemokine (especially CCR3) activity | ASTRAZENECA AB (SE) | 2007-07-03 | — | — | US | disclosed |
| EP-1430050-B1 | PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE (ESPECIALLY CCR3) ACTIVITY | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| EP-1487793-A1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2004-12-22 | — | — | EP | disclosed |
| US-20040242577-A1 | Piperdine derivatives and their use as modulators of chemokine (especially ccr3) activity | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
| EP-1430050-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE (ESPECIALLY CCR3) ACTIVITY | AstraZeneca AB (SE) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003078395-A1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003024962-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE (ESPECIALLY CCR3) ACTIVITY | ASTRAZENECA AB (SE) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242577-A1 | Piperdine derivatives and their use as modulators of chemokine (especially ccr3) activity | CCR3, CCR1, CCR2 | HRH1 34/4885CCR3 1/4885SLC6A2 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.